Physician

David Donald Wright, MD

According to 2025 Medicare claims, David Wright, MD (NPI: 1699745638) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hillsborough, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33607-6214.

Wright's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,266 traditional Medicare patients, billed 280,435 HCPCS/CPT codes, and received $4,717,294 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,815 prescription claims across 389 beneficiaries totaling $6,946,753 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 84 claims. Open Payments data shows 237 records totaling $544,157. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,610,715 to $6,946,753. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $5,380 and ending at $4,886.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,385	248,597	$4,480,974
2016	1,455	336,257	$5,412,018
2017	1,464	349,700	$5,528,389
2018	1,612	393,215	$6,354,892
2019	1,950	413,921	$6,311,555
2020	1,749	380,881	$6,583,451
2021	1,389	331,899	$5,943,807
2022	1,296	351,950	$5,337,214
2023	1,315	319,595	$4,794,754
2024	1,266	280,435	$4,717,294

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	332	1,742	$1,610,715
2016	340	1,904	$2,096,937
2017	376	2,018	$3,276,698
2018	407	2,060	$4,166,711
2019	450	2,376	$5,878,470
2020	441	2,404	$7,376,171
2021	418	2,186	$6,925,245
2022	422	2,042	$7,258,851
2023	404	1,851	$7,106,837
2024	389	1,815	$6,946,753

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	115	$23,147
2016	N/R	217	$77,373
2017	12	136	$65,153
2018	N/R	172	$36,137
2019	12	146	$12,375
2020	N/R	196	$53,170
2021	N/R	132	$9,221
2022	N/R	72	$6,788
2023	N/R	84	$8,680
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	721	1,742	$92
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	624	1,037	$13
96372	Injection of drug or substance under skin or into muscle	340	1,538	$10
36415	Insertion of needle into vein for collection of blood sample	946	2,693	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	948	2,883	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	138	3,598	$2,033,507
Jakafi	Ruxolitinib Phosphate	36	1,080	$616,414
Pomalyst	Pomalidomide	27	756	$603,874
Imbruvica	Ibrutinib	33	1,110	$518,294
Ibrance	Palbociclib	33	917	$511,757

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	220	$4,692	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	17	$539,465	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David Donald Wright, MD?

Tedicare shows public-source Medicare data for David Donald Wright, MD (NPI 1699745638), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David Donald Wright, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to David Donald Wright, MD?

David Donald Wright, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does David Donald Wright, MD have Open Payments data?

David Donald Wright, MD has 237 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.